MarketVIEW: Respiratory Syncytial virus vaccines

  • May 2012
  • -
  • VacZine Analytics Group Of Assay Advantage Ltd
  • -
  • 60 pages

Respiratory syncytial virus (RSV) is a leading cause of infant/childhood lower respiratory tract infection and hospitalization. Elderly adults and those with underlying co-morbidities such as chronic obstructive pulmonary disease (COPD) or suffering with malignancies are also at increased risk of RSV infection related complications. RSV is estimated to be responsible for ~9,000 deaths per year (US).

An RSV prophylactic vaccine would ideally to reduce the incidence of severe RSV lower respiratory tract infections in "at risk" groups. Currently a number of approaches are being pursued including live-attenuated viruses and/or recombinant proteins, the most advanced of which is AstraZeneca/Medimmune's MEDI-534 and MEDI-559. US biotech Novavax have also completed a Phase I trial with VLP recombinant RSV-F fusion protein. 

This MarketVIEW is a comprehensive MS Excel-based model + summary presentation which forecasts the potential commercial value of new RSV vaccines across global markets to 2030. The model contains value ($ m) and volume (mio doses) predictions for infants (<1yrs) and various adult target groups. Differing RSV vaccine profiles (infant + elderly) and related issues such as differential pricing are also discussed with regard to LO/BASE/HI market uptake scenarios. 

THIS PRODUCT IS A SUMMARY PRESENTATION + MODEL 

Table Of Contents

Executive summary
Commercial model - key outputs
Total predicted demand (doses 000s), all scenarios
Total global available market ($000s), all scenarios
Total global available market ($000s), infant
Total global available market ($000s), adult “at risk”
Total global available market ($000s), adult “universal”
The role of a RSV vaccine
Vaccine target populations: overview
Vaccine target populations: scenario definitions
RSV vaccine: infant target product profile
RSV vaccine: adult target product profile
Markets included in the model
Commercial model assumptions: infant scenario
Commercial model assumptions: adult scenarios
Model forecast comparisons: March 2010 v current model (May 2012)
Pricing methodology: infant and adults
Competitor landscape overview
MedImmune: MEDI-534 and MEDI-559 vaccines
Novavax: VLP RSV-F vaccine
Novavax: Phase I data
Preclinical vaccines
Vaccine pipeline summary
Estimated launch dates
Opportunities for new treatments
Review of latest epidemiology
Epidemiology: infants
Epidemiology: adults
Epidemiology: hospitalizations
Methodology: target populations
Methodology: coverage
Model forecast comparisons: Novavax/LEK analysis
Bibliography
About VacZine Analytics
Disclaimer
PAGES: 60 MS PowerPoint slides, fully referenced/sourced. Available in .pdf form
Contents - Vaccine demand model (MS Excel-based)
Title sheet
Scenarion definitions
GRAND SUMMARY CHARTS
CHARTS VALUE
CHARTS VOLUME
CHARTS VOLUME - HIGH
VALUE SUMMARY - universal
VALUE SUMMARY - “at risk”
VALUE SUMMARY - infants
VOLUME SUMMARY - universal
VOLUME SUMMARY - “at risk”
VOLUME SUMMARY - infants
Country volume/population sheets
US
Canada
UK
Germany
France
Spain
Italy
Other EU
Japan
Brazil
India
China
Mexico
Country total populations - forecast to 2030 (Births, >18 yrs, >65 yrs)
Source material
US RSV
Japan RSV
US Pneumonia
Asthma/COPD epidemiology
CHF epidemiology
Cancer EPI
Pricing (infant)
Coverage (COPD and HF)
Back page
About VacZine Analytics
Disclaimer
WORKSHEETS: ~65

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Louis

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers

PharmaPoint: Migraine - Global Drug Forecast and Market Analysis to 2023

PharmaPoint: Migraine - Global Drug Forecast and Market Analysis to 2023

  • $ 9 995
  • Industry report
  • March 2014
  • by Global Data

PharmaPoint: Migraine - Global Drug Forecast and Market Analysis to 2023 Summary The migraine market is saturated with generic drugs, and the remaining branded products already on the market are expected ...

Antibiotics: Technologies and Global Markets

Antibiotics: Technologies and Global Markets

  • $ 6 650
  • Industry report
  • May 2014
  • by BCC Research

Use this report to: - Identify the major market trends and the factors driving or inhibiting the growth of the global pharmaceutical antibiotics market and its various submarkets. - Learn about developments ...

Antifungal Drugs : Technologies and Global Markets

Antifungal Drugs : Technologies and Global Markets

  • $ 6 650
  • Industry report
  • June 2014
  • by BCC Research

This report aims to determine the current status of the global human antifungal market and assess its growth potential over the five-year period from 2013 through 2018. It covers approved human therapeutics ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.